Boosting the Pipeline: Sotac Pharmaceuticals Lands Major Intas Order

Sotac Pharmaceuticals Limited announced on July 23, 2026, that it has secured a major purchase order valued at Rs. 97,57,200 (exclusive of goods and services tax) from prominent domestic drug manufacturer Intas Pharmaceuticals Limited. The official disclosure, submitted under regulatory guidelines to the National Stock Exchange of India (NSE), highlights that the contract entails the supply of finished pharmaceutical formulations, specifically incorporating various strengths of Entacom and Entacom Plus tablets. This development reinforces manufacturing operations at Sotac Pharmaceuticals and validates ongoing business confidence from established industry leaders.

Details of the Pharmaceutical Formulation Order

The procurement contract covers high-demand therapeutic batches, including Entacom 10-tablet strips along with Entacom Plus variants in 50mg, 100mg, and 150mg formulations. Production and supply chains will be managed through Sotac Pharmaceuticals' established facilities, adhering strictly to quality compliance benchmarks. Market analysts note that order fulfillment of this scale contributes positively to the company's operational revenue consistency for the ongoing fiscal quarter.

Corporate Background and Market Significance

Sotac Pharmaceuticals operates extensively in the contract manufacturing and loan-licensing space, producing a wide array of tablets, capsules, and oral liquids for major pharmaceutical marketers. Securing high-value orders from established multinational entities like Intas Pharmaceuticals Limited underscores the company's technical reliability and adherence to regulatory standards. This partnership supports steady capacity utilization across its manufacturing plants in Gujarat.

Regulatory Filings and Official Statements

According to regulatory disclosures filed by Sotac Pharmaceuticals Limited, the agreement was formally finalized on July 22, 2026. The filing was authorized by company leadership, emphasizing full compliance with disclosure norms.

"According to officials, the latest order significantly augments the company's existing order book and reflects continued business confidence from a well-established domestic pharmaceutical company."

Why It Matters

For investors and industry stakeholders, repeat and high-value purchase orders validate the commercial viability of contract-manufacturing business models. For Sotac Pharmaceuticals Limited, scaling production pipelines for established brands like Intas Pharmaceuticals Limited strengthens revenue predictability and supports long-term growth objectives within the competitive healthcare sector.

Key Facts at a Glance

• Order Value: Rs. 97,57,200 (approx. Rs. 9.8 million) excluding GST.

• Client Partner: Intas Pharmaceuticals Limited.

• Product Scope: Finished pharmaceutical formulations including Entacom and Entacom Plus tablet ranges.

• Regulatory Compliance: Disclosed formally under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

FAQ Section

What is the value of the purchase order received by Sotac Pharmaceuticals?

The purchase order is valued at Rs. 97,57,200 (exclusive of GST), amounting to approximately Rs. 9.8 million.

Which company placed the order with Sotac Pharmaceuticals?

The order was placed by Intas Pharmaceuticals Limited.

What products are included in the supply agreement?

The agreement covers finished pharmaceutical formulations consisting of Entacom 10-tablet packs and multiple strengths of Entacom Plus tablets.

Where was the regulatory disclosure published?

The official corporate communication was submitted to the National Stock Exchange of India (NSE).

Source: National Stock Exchange of India (NSE), Intas Pharmaceuticals Limited, Sotac Pharmaceuticals Limited Regulatory Filings